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ABSTRACT
In our study, we investigated the role of ZNF677 in non-small cell lung 
cancers (NSCLC). By comparing ZNF677 expression in primary tumor (TU) and 
in the majority of cases also of corresponding non-malignant lung tissue (NL) 
samples from > 1,000 NSCLC patients, we found tumor-specific downregulation of 
ZNF677 expression (adjusted p-values < 0.001). We identified methylation as main 
mechanism for ZNF677 downregulation in NSCLC cells and we observed tumor-specific 
ZNF677 methylation in NSCLC patients (p < 0.0001). In the majority of TUs, ZNF677 
methylation was associated with loss of ZNF677 expression. Moreover, ZNF677 
overexpression in NSCLC cells was associated with reduced cell proliferation and 
cell migration. ZNF677 was identified to regulate expression of many genes mainly 
involved in growth hormone regulation and interferon signalling. Finally, patients 
with ZNF677 methylated TUs had a shorter overall survival compared to patients 
with ZNF677 not methylated TUs (p = 0.013). Overall, our results demonstrate that 
ZNF677 is trancriptionally regulated by methylation in NSCLCs, suggest that ZNF677 
has tumor cell growth suppressing properties in NSCLCs and that ZNF677 methylation 
might serve as prognostic parameter in these patients.
INTRODUCTION
Gene expression in malignant tumors may be 
affected by genetic and epigenetic changes. In non-small 
cell lung cancers (NSCLC) many genes are already known 
whose function is influenced by genetic abnormalities 
and some of them are also of clinical relevance [1–3]. 
DNA methylation (referred to as methylation) which 
is an epigenetic change was identified as alternative 
mechanism to transcriptionally regulate expression of 
certain genes. Methylation describes the covalent addition 
of a methyl group to the 5′ carbon of cytosine bases within 
cytosine-guanine (CpG) dinucleotides located at high 
density in CpG islands (CGI) leading to transcriptional 
gene silencing [4]. It may be reversible by DNA 
methyltransferase inhibitors like 5-aza-2′-deoxycytidine 
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(Aza-dC) and a synergistic effect in upregulation of gene 
expression together with histone deacetylase inhibitors 
like trichostatin A (TSA) was described [5, 6].
So far, many genes were found which are 
transcriptionally inactivated by methylation in NSCLCs 
[7–12]. We recently identified ~500 tumor-specifically 
methylated genes when we used a genome-wide approach 
to search for methylated genes in NSCLC patients [7].
In addition, to obtain information about expression 
of these genes, we used publicly available gene expression 
microarray data of primary tumor (TU) and corresponding 
non-malignant lung tissue (NL) samples of a large number 
of NSCLC patients [13, 14]. Many genes which have been 
identified in our study to be tumor-specifically methylated 
exhibited downregulated expression in TU compared to 
NL samples of these patients. One of them is the zink 
finger protein 677 (ZNF677). This gene is located at the 
chromosomal region 19q13, a region where frequent loss 
of heterozygosity in NSCLCs occurs [15, 16]. Because our 
initial results suggested that ZNF677 is involved in the 
pathogenesis of NSCLCs and only little information about 
this gene is currently available, we decided to further 
investigate this gene. Thus, we determined ZNF677 
mRNA expression, methylation and re-expression in 
NSCLC cell lines, we investigated ZNF677 methylation in 
clinical samples of a large number of NSCLC patients and 
we compared ZNF677 methylation with ZNF677 protein 
expression in tissue samples of some of these patients. 
In addition, we analysed tumor cell growth suppressing 
properties of ZNF677 and determined molecular pathways 
which are affected by ZNF677. Finally, we compared 
ZNF677 methylation results of TU samples with clinico-
pathological characteristics of the NSCLC patients.
Overall, our results indicate that ZNF677 is 
frequently transcriptionally silenced by methylation 
in NSCLCs and they suggest that ZNF677 has tumor 
cell growth suppressing properties. Moreover, ZNF677 
methylation might be of prognostic relevance for NSCLC 
patients.
RESULTS
ZNF677 expression in clinical samples of NSCLC 
patients using ArrayExpress and TCGA datasets
We analysed 2 publicly available microarray 
datasets from ArrayExpress database to investigate 
ZNF677 expression in TU and NL samples of NSCLC 
patients. While ZNF677 expression was observed in 
all NL samples, downregulated ZNF677 expression 
was found in TU samples of both datasets analysed 
(Figure 1A). A statistically significant downregulation of 
ZNF677 expression in TU compared to NL samples was 
observed in dataset E-GEOD-18842 (Bonferroni adjusted 
p-value = 0.00003) and similar results were seen in dataset 
E-GEOD-19188 (Bonferroni adjusted p-value = 0.0007).
To confirm tumor-specific downregulation of ZNF677 
expression observed by gene expression microarray 
analyses, we additionally compared ZNF677 RNA-seq 
expression values in TU and NL samples of LUAD and 
LUSC datasets obtained from the Cancer Browser database 
[17]. Consistent to the data obtained by gene expression 
microarray analyses, a statistically significant tumor-
specific downregulation of ZNF677 expression in NSCLC 
patients ( p = 2.7 * 10−21) was found (Figure 1B).
We also investigated if downregulation of 
ZNF677 expression differs between NSCLC subtypes 
“adenocarcinoma” (ADC), “squamous cell carcinoma” 
(SCC) and “large cell carcinoma”. While in dataset 
E-GEOD-18842 ZNF677 expression was lower in SCC 
samples compared to ADC samples (p = 0.004), no 
statistically significant differences of ZNF677 expression 
between NSCLC subtypes were observed in dataset 
E-GEOD-19188 and in the TCGA NSCLC datasets.
ZNF677 expression in other tumor entities using 
TCGA datasets
Because we were interested if ZNF677 expression is 
also deregulated in tumors of other entities, we analysed 
ZNF677 expression in primary TU and non-malignant 
tissue samples from patients with other malignancies 
than NSCLC using TCGA RNA-seq datasets from the 
Cancer Browser database [17]. We found tumor-specific 
ZNF677 downregulation in “breast invasive carcinoma” 
( p = 8.2 * 10−46), “colon and rectum adenocarcinoma” 
( p = 1.5 * 10−7), “kidney renal clear cell carcinoma” 
( p = 1 * 10−20), “head and neck squamous cell carcinoma” 
(p = 1 * 10−11) and “uterine corpus endometrioid carcinoma” 
(p = 0.001) patients (supplementary Figure S1).
Overall, these data indicate that ZNF677 expression 
is tumor-specifically downregulated in different solid 
tumor types including NSCLCs.
ZNF677 expression in NHBECs and in NSCLC 
cell lines
To further investigate ZNF677 expression, we 
analysed NHBECs and NSCLC cell lines A549, Calu-6, 
HCC827, NCI-H1975, NCI-H1993 and NCI-H2073 for 
ZNF677 expression by RT-PCR. ZNF677 expression was 
observed in NHBECs and in HCC827 and NCI-H1975 
cells, but was not detected in A549, Calu-6, NCI-H1993 
and NCI-H2073 cells (Figure 2A). GAPDH expression 
was seen in all samples at comparable Ct values.
ZNF677 methylation in NHBECs and in NSCLC 
cell lines
To study the mechanism responsible for ZNF677 
silencing in many NSCLC cell lines, we developed a 
MS-HRM assay to determine methylation of the 5′ region 
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of ZNF677. As expected, NHBECs were found to be 
not ZNF677 methylated (Figure 2B). While all ZNF677 
not expressing cell lines (A549, Calu6, NCI-H1993 and 
NCI-H2073) were identified to be ZNF677 methylated, the 
2 ZNF677 expressing cell lines HCC827 and NCI-H1975 
were found to be not ZNF677 methylated. In addition, 
to demonstrate that methylation of ZNF677 is indeed 
associated with its transcriptional regulation, we treated 
cells of ZNF677 methylated cell lines A549, Calu6, 
NCI-H1993 and NCI-H2073 with Aza-dC and TSA and 
compared ZNF677 expression in treated and untreated 
cells by RT-PCR. ZNF677 expression was found to be 
upregulated in cells of all drug treated NSCLC cell lines 
analysed with mean fold changes in expression ranging 
from 2.5-fold to 2349-fold (Figure 2C).
To confirm data obtained by MS-HRM analyses, we 
additionally performed BGS of a part of the 5′ region of 
ZNF677 in NHBECs and in A549, Calu6 and NCI-H2073 
cells. Genomic regions selected for BGS contained 
regions analysed by MS-HRM. In total, 50 CpG sites were 
analysed for ZNF677 methylation (Figure 2D). While in 
A549, Calu6 and NCI-H1975 cells 64%, 82% and 85% of 
Figure 1: Comparison of ZNF677 expression values based on gene expression microarray data and RNA-seq data 
of NL and primary TU samples from NSCLC patients. (A) Log2 transformed ZNF677 expression values of 2 independent 
Affymetrix HG-U133_plus_2.0 datasets are shown. Each dot represents a unique tissue sample. NL, non-malignant lung tissue; TU, 
primary tumor. (B) The heatmap summarises RNA-seq data of ZNF677 in 1061 clinical samples of NSCLC patients obtained from LUAD 
and LUSC datasets. Dark blue, adenocarcinomas; light blue, squamous cell carcinomas.
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CpG sites analysed were found to be ZNF677 methylated, 
respectively, in NHBECs only 2% of CpG sites were found 
to be ZNF677 methylated. Differences in methylation of 
ZNF677 in A549 cells and NHBECs, in Calu6 cells and 
NHBECs and in NCI-H2073 cells and NHBECs were 
statistically significant (Bonferroni adjusted p < 0.001).
ZNF677 methylation in cell lines  
of other tumor entities
In addition, we analysed ZNF677 methylation in 
cell lines of other tumor entities including breast cancer 
(N = 5), colon cancer (N = 2), ovarian cancer (N = 2), 
pancreatic cancer (N = 2) and head and neck cancer 
(N = 2) by MS-HRM (supplementary Figure S2). All these 
tumor cell lines except 1 breast cancer (MDA-MB-468) 
and 1 ovarian cancer (SCOV3) cell line were found to be 
ZNF677 methylated. By comparing methylation values 
of these cell lines with ZNF677 mRNA expression values 
from the TCGA Cancer Cell Line Encyclopedia, a strong 
negative correlation between ZNF677 methylation and 
ZNF677 expression in these cell lines was observed 
(R = −0.889, p < 0.0001; supplementary Figure S2).
Overall, these results suggest that methylation of the 
5´ region of ZNF677 is responsible for ZNF677 silencing 
in many tumor cell lines of different entities including 
Figure 2: ZNF677 expression and ZNF677 methylation in NHBECs and in NSCLC cells. (A) ZNF677 expression was 
determined by RT-PCR using Taqman assays and normalised to GAPDH. (B) ZNF677 methylation determined by MS-HRM analyses 
in NHBECs and in 6 NSCLC cell lines. All NSCLC cell lines found to be negative for ZNF677 expression were found to be ZNF677 
methylated. (C) A549, NCI-H1993, Calu6 and NCI-H2073 cells were treated with a combination of Aza-dC and TSA. ZNF677 expression 
was found to be upregulated in all drug treated cells determined by RT-PCR. The fold change in expression of drug treated cells compared 
to untreated cells is shown. (D) Results from BGS of a part of the ZNF677 5´ region in NHBECs and in A549, Calu6 and NCI-H2073 
cells are demonstrated. Overall, 50 CpG sites (pink bars) were analysed for methylation. The transcription start site is shown as blue bar. 
Four clones per sample were sequenced. Black squares indicate methylated cytosines at CpG sites, white squares indicate unmethylated 
cytosines at CpG sites and grey squares indicate CpG sites which were not evaluable.
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NSCLC, breast cancer, colon cancer, ovarian cancer, 
pancreatic cancer and head and neck cancer.
ZNF677 methylation in NSCLC patients
We also investigated ZNF677 methylation in TU 
and NL samples of 147 stage I-III NSCLC patients by 
MS-HRM (Figure 3A). Differences in methylation 
between TU and NL samples were statistically significant 
( p = 1.3 * 10−20) demonstrating that ZNF677 is tumor-
specifically methylated (Figure 3B). The mean % of 
ZNF677 methylation was 19 (range −4% – 84%) in TU 
and 1 (range −4% – 38%) in NL samples, respectively 
(Figure 3B). In addition, ROC curve analyses revealed 
that methylation of ZNF677 statistically significant 
distinguishes TU from NL samples ( p = 1.1 * 10−23; area 
under the curve: 0.838; 95% CI: 0.792 – 0.885; Figure 3B).
For comparison of ZNF677 methylation data 
with clinico-pathological characteristics of the NSCLC 
patients, patients were grouped into “high ZNF677 TU 
methylation” and “low ZNF677 TU methylation” using 
the mean % of ZNF677 methylation in TU samples as 
cut-off level [18]. Data about DFS and OS were available 
for 97 patients, respectively. Patients with “high ZNF677 
TU methylation” had a statistically significant shorter 
OS than patients with “low ZNF677 TU methylation” 
in univariate analyses (median survival: 39 months 
vs. not reached, p = 0.013; Figure 3C). In addition, 
multivariate analyses identified ZNF677 TU methylation 
as independent prognostic factor for shorter OS of NSCLC 
patients (hazard ratio [HR] = 1.8, 95% confidence interval 
[CI] = 1 to 3.1, p = 0.046). No other statistically significant 
associations between ZNF677 methylation and clinico-
pathological characteristics of the patients were observed. 
We also compared ZNF677 mRNA expression in TU 
samples and OS of patients in the LUAD and LUSC 
datasets and, additionally, in a combined version of these 
2 datasets (LUAD + LUSC). While we found a shorter OS 
for patients with ZNF677 low expressing tumors compared 
to ZNF677 high expressing tumors in LUAD ( p = 0.015) 
and in the LUAD + LUSC ( p = 0.029) datasets, we did not 
find a correlation in the LUSC dataset.
Overall, these results demonstrate that ZNF677 
is tumor-specifically methylated in NSCLC patients. 
Moreover, they suggest that ZNF677 methylation and 
ZNF677 mRNA expression might be of prognostic impact 
for certain NSCLC patients, however, additional studies 
are necessary to determine the potential clinical relevance.
IHC
We also performed IHC of ZNF677 in FFPE TU 
samples of a subgroup of 35 NSCLC patients which were 
also analysed by MS-HRM. A NL sample was used as 
positive control and nuclear and cytoplasmic ZNF677 
expression was observed in bronchial and bronchiolar 
epithelial cells of this sample (Figure 3D). 43% of the 
TU samples were scored as negative for ZNF677 protein 
expression by IHC. Representative stainings are shown in 
Figure 3D.
In addition, we compared ZNF677 methylation and 
ZNF677 protein expression in TU samples. In the majority 
of TU samples the detection of ZNF677 methylation was 
associated with downregulated ZNF677 protein expression. 
In addition, TU samples which were found to be not 
ZNF677 methylated mostly expressed ZNF677. However, 
these results did not reach statistical significance. Thus, we 
compared methylation and expression data from LUAD and 
LUSC datasets and we found a strong negative correlation 
between ZNF677 methylation and ZNF677 expression in 
both datasets (R = −0.673 and R = −0.654, respectively; 
p < 0.000001, respectively; supplementary Figure S2C).
ZNF677 mutations and copy number changes in 
NSCLC patients
Moreover, we were interested if besides methylation 
also mutations or copy number changes might be 
responsible for downregulated ZNF677 expression in 
NSCLC patients. Thus, we searched for ZNF677 mutations 
in LUAD and LUSC datasets. ZNF677 mutations 
including 1 splice variant and 6 missense mutations 
(C232S, H477N, G254W, C492F, H281Y and P514T) 
were found only in 2% of both ADC and SCC patients and 
their localisation is shown in supplementary Figures S3A 
and S3B. All ZNF677 mutations were mutually exclusive. 
Mutations H477N and C492F were predicted to have a 
high functional impact (supplementary Figure S3C).
In addition, we searched for ZNF677 copy number 
changes in LUAD and LUSC TCGA aCGH datasets of 
983 NSCLC patients. A homozygous ZNF677 deletion 
was detected only in 1 ADC patient (supplementary 
Figures S3D and S3E), however, heterozygous ZNF677 
deletions were found in 34% of ADC patients and in 
25% of SCC patients. Overall, the pattern of ZNF677 
copy number aberrations was comparable to that of other 
genes known to be frequently inactivated by methylation 
in NSCLC patients (e.g. p16, RASSF1A, DAPK1, DAL-1, 
CDH1; supplementary Figures S3D and S3E) [8, 9, 19]. 
Copy number alterations did not correlate with changes in 
ZNF677 expression.
These results demonstrate that heterozygous 
ZNF677 deletions but not ZNF677 mutations occur 
frequently in NSCLCs indicating that ZNF677 mutations 
do not play a role in inactivation of ZNF677 in NSCLCs.
Effect of ZNF677 expression on cell viability, cell 
proliferation, apoptosis and cell migration
To investigate the biologic effect of ZNF677 
expression in NSCLC cells, we stably transfected A549, 
NCI-H2073 and NCI-H1993 cells with a pCMV6-
ZNF677 expression vector, with a pCMV6-ENTRY 
(empty vector) and with a pCMV6-GFP control vector. 
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Figure 3: ZNF677 methylation and ZNF677 expression in clinical samples of NSCLC patients. (A) A part of the ZNF677 
5´ region was amplified (left), PCR products were subjected to high resolution melting and fluorescence values were normalised against 
0% methylated DNA standards (middle). The regression line of maximum peak values was used for calculation of methylation percentages 
(right). (B) Comparison of % of ZNF677 methylation in TU and NL samples of 147 NSCLC patients reveals statistically significant 
differences of ZNF677 methylation. Each dot represents the % of methylation of an individual sample (left). ROC curve analysis of 
ZNF677 methylation in TU and NL samples of 147 NSCLC patients is illustrated (middle). Blue line, reference line; red line, methylation 
of particular gene; AUC, area under the curve; CI, confidence interval. (C) The impact of ZNF677 methylation on the OS of 97 NSCLC 
patients is shown. Kaplan-Meier plot demonstrates a statistically significant shorter OS of NSCLC patients with high ZNF677 methylation 
compared to NSCLC patients with low ZNF677 methylation. (D) Immunohistochemical staining of a NL sample (left), of a ZNF677 
methylated TU sample (middle) and of a ZNF677 not methylated TU sample (right) using an antibody to ZNF677 is shown. While nuclear 
and cytoplasmic ZNF677 expression was observed in bronchial and bronchiolar cells of the NL sample, lack of ZNF677 expression was 
observed in ZNF677 methylated tumor cells.
Using light microscopy, we observed strongly reduced cell 
growth in pCMV6-ZNF677 transfected cells compared 
to empty vector control cells (Figure 4A). ZNF677 
overexpression was confirmed by RT-PCR and Western 
blotting (Figure 4B and 4C). Reduced cell growth (1.4 to 
3.6-fold, mean 2.7-fold) of pCMV6-ZNF677 transfected 
A549, NCI-H2073 and NCI-H1993 cells was confirmed 
using a cell viability assay (Figure 4D). In addition, cell 
proliferation of transfected cells was measured over 
time and reduced cell proliferation of pCMV6-ZNF677 
transfected cells compared to control cells was observed 
confirming our cell viability assay results (Figure 4E).
No effect of ZNF677 expression on Caspase 3 
activity was observed (data not shown). However, we 
observed a reduced migration capacity of pCMV6-ZNF677 
transfected cells compared to cells transfected with the 
empty control vector by using a scratch assay (Figure 4F).
Overall, these findings suggest that ZNF677 affects 
cell proliferation and migration of NSCLC cells A549, 
NCI-H1993 and NCI-H2073.
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Figure 4: Cell viability, cell proliferation and cell migration of pCMV6-ZNF677 transfected NSCLC cells. 
(A) NCI-H1993 pCMV6-ENTRY cells were densely grown after 4 weeks of G418 treatment (left), however, reduced growth of NCI-H1993 pCMV6-
ZNF677 cells was observed (right). (B) While GAPDH expression was detected in all samples analysed (a), ZNF677 was detected in pCMV6-
ZNF677 transfected cells (b) but not in control cells (c) by RT-PCR. (C) ZNF677 overexpression confirmed by Western blotting in pCMV6-
ENTRY and pCMV6-ZNF677 transfected A549 and NCI-H2073 cells. (D) Reduced cell viability of pCMV6-ZNF677 transfected A549, 
NCI-H1993 and NCI-H2073 cells compared to control cells was observed. Experiments were performed in triplicates. Error bars indicate 
standard deviations. (E) Reduced cell proliferation of pCMV6-ZNF677 transfected A549, NCI-H1993 and NCI-H2073 cells compared to 
controls using xCELLigence RTCA system was observed. Each cell line was plated in triplicates. Error bars indicate standard deviations. 
(F) Scratch assay of NCI-H2073pCMV6-ENTRY and NCI-H2073pCMV6-ZNF677 cells demonstrates a faster closure of the scratch in NCI-H2073pCMV6-
ENTRY cells compared to NCI-H2073pCMV6-ZNF677 cells.
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Transcriptional gene regulation by ZNF677
Finally, we determined the effect of ZNF677 
expression on the transcriptome of A549, NCI-H1993 
and NCI-H2073 cells by RNA-seq. Overall, ZNF677 
overexpression resulted mainly in upregulation of 
target genes (Figure 5A). We identified 198, 71 and 
83 differentially expressed genes in pCMV6-ZNF677 
transfected A549, NCI-H1993 and NCI-H2073 cells 
compared to control cells, respectively (Figure 5B, 
supplementary Table S1). By comparing differentially 
expressed genes in the 3 NSCLC cell lines, we identified 
34 genes which are regulated by ZNF677 in at least 2 
of the cell lines (Figure 5C). Four of these genes were 
found to be downregulated (GH1, GH2, CSH1 and CSH2), 
27 of them were found to be upregulated and 3 genes 
were found to be either down- or upregulated. These 34 
genes were further categorized based on Gene Ontology 
(supplementary Figure S4) and protein expression of some 
of them was analysed by Western blotting (supplementary 
Figure S5). Several genes whose expression was found to 
be upregulated in these cells are associated with “immune 
effector process” (adjusted p = 1.7 * 10−5), “response to 
cytokine” (adjusted p = 0.002), “type I interferon signaling 
pathway” (adjusted p = 9.4 * 10−10) and “response to 
virus” (adjusted p = 1.3 * 10−8). Similar results were 
observed by analysing GO enrichment using genes 
with induced expression in “ZNF677 high expressing” 
compared to “ZNF677 low expressing” primary TU 
samples of ArrayExpress datasets E-GEOD-18842 and 
E-GEOD-19188 (supplementary Table S2).
These results demonstrate that ZNF677 is a 
transcriptional regulator of genes involved in growth 
signaling and interferon signaling pathways in NSCLC cells.
Figure 5: Effect of ZNF677 overexpression on the transcriptome of NSCLC cells. (A) Scatter plots showing ZNF677 regulated 
genes in pCMV6-ZNF677 transfected A549, NCI-H1993 and NCI-H2073 cells compared to control cells analysed by RNA-seq. Red dots 
indicate statistically significant deregulated genes. (B) The venn diagram summarizes the overlap of ZNF677 regulated genes in A549, 
NCI-H1993 and NCI-H2073 cells. (C) The heatmap shows expression values of 34 genes found to be either up- or downregulated in at 
least 2 pCMV6-ZNF677 transfected NSCLC cell lines compared to control cells. Expression values range from yellow (high) to blue (low).
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DISCUSSION
In a recent genome-wide search for CGI methylation 
in a large number of NSCLC patients, we identified 477 
tumor-specifically methylated genes and from the majority 
of them regulation by methylation and/or an involvement in 
the pathogenesis of NSCLCs was unknown so far [7]. One 
of these genes is ZNF677 and except the report from Li et 
al. who described some genomic aberrations of ZNF677 in 
gliomas no manuscripts about the involvement of ZNF677 
in cancer development was published so far [20]. Thus, we 
decided to further investigate the role of ZNF677 in NSCLCs.
Large datasets from genome-wide gene expression 
analyses regarding NSCLCs are publically available [13, 
14, 21]. Hou et al. identified 588 unique genes with tumor-
specifically downregulated expression by comparing mRNA 
expression profiles between TU and corresponding NL 
samples of NSCLC patients using gene expression microarray 
analyses (E-GEOD-19188) and similar results were reported 
by Sanchez-Palencia et al. (E-GEOD-18842) [13, 14]. In 
our study, we used these 2 datasets to search for tumor-
specific differences of ZNF677 expression. After multiple 
comparison adjustment, we identified ZNF677 expression 
to be statistically significantly downregulated in TU 
compared to NL samples of NSCLC patients in both datasets. 
Tumor-specific downregulation of ZNF677 expression in 
NSCLC patients was confirmed by RNA-seq expression 
values from the TCGA database [22, 23]. Moreover, 
we found tumor-specific downregulation of ZNF677 
expression also in breast carcinomas, colon and rectum 
adenocarcinomas, renal clear cell carcinomas, head and 
neck squamous cell carcinomas and endometrioid carcinomas 
suggesting that ZNF677 may play an important role also in 
the pathogenesis of several other malignant diseases.
Since we had ZNF677 identified to be tumor-
specifically methylated in our genome-wide methylation 
analyses before, we used single-gene analyses to confirm 
methylation of ZNF677 in several NSCLC cell lines. 
NSCLC cells which did not express ZNF677 were found 
to be ZNF677 methylated and treatment of these cells 
with epigenetically active drugs resulted in upregulation 
of ZNF677 expression. ZNF677 mutations were found in 
only 2% of the tumors using TCGA datasets. In addition, 
we observed an association between ZNF677 methylation 
and loss of ZNF677 expression for the majority of TU 
samples analysed while ZNF677 not methylated TU 
samples mostly expressed ZNF677. However, these 
results did not reach statistical significance which might 
be explained by the low number of samples available for 
this analysis. Moreover, we used tissue microarrays from 
the tumor samples which represent only a small part of 
the tumor. Because of heterogeneity of tumor cells within 
a tumor, we cannot exclude that heterogeneity of ZNF677 
protein expression might have influenced our results.
However, we were able to demonstrate that 
downregulated ZNF677 expression is strongly correlated 
with increased ZNF677 methylation in primary TU 
samples of LUAD and LUSC datasets. Overall, these 
results indicate that methylation is a major mechanism for 
transcriptional regulation of ZNF677.
We also analysed TU and NL samples of a large 
number of NSCLC patients and identified statistically 
significant tumor-specific ZNF677 methylation. Moreover, 
ROC curve analyses of MS-HRM results statistically 
significantly distinguished TU from NL samples. In 
addition, we compared our ZNF677 methylation results with 
certain clinico-pathological characteristics of the NSCLC 
patients and observed a shorter OS of patients with ZNF677 
methylated tumors compared to patients with ZNF677 not 
methylated tumors. These results suggest that ZNF677 
methylation might be of potential prognostic relevance, 
however, additional studies are necessary to confirm our 
results. Since we found in an exploratory analysis using 
LUAD and LUSC datasets that downregulated ZNF677 
expression is associated with a shorter OS in a subgroup 
of NSCLC patients, also ZNF677 expression might be of 
potential prognostic impact. In contrast to some genetic 
changes which occur only in certain histologic NSCLC 
subtypes, we did not find a statistically significant difference 
in ZNF677 methylation between tumors with squamous and 
with non-squamous histology [1–3].
Certain characteristics of tumor suppressor genes 
(TSG) include that they are often located in chromosomal 
regions with frequent loss of heterozygosity (LOH), that 
they may become inactivated by genetic or epigenetic 
mechanisms and that they may inhibit tumor cell growth 
[24]. ZNF677 is located at the chromosomal region 19q13 
which is frequently affected by LOH in NSCLCs [15, 16]. 
Moreover, we found ZNF677 to be frequently inactivated 
in NSCLC cell lines and in primary NSCLCs. Thus, we 
investigated if ZNF677 has tumor cell growth suppressing 
properties. Overall, in NSCLC cell line experiments, 
we observed a strongly reduced tumor cell growth and 
reduced cell motility of ZNF677 overexpressing cells 
compared to control cells. Reduced tumor cell growth 
was observed in all 3 NSCLC cell lines analysed with 3 
different assays which suggests that ZNF677 has intrinsic 
tumor cell growth suppressing function.
Moreover, to uncover molecular pathways affected 
by ZNF677 expression in NSCLC cells, we compared the 
transcriptome of ZNF677 transfected cells with control cells 
using RNA-seq technology. The small overlap between 
A549 cells and cells from the other 2 tumor cell lines 
(NCI-H1993 and NCI-H2073) might be explained by the 
different biology of these cells. While A549 is described as 
a mesenchymal-like cell line, NCI-H1993 and NCI-H2073 
are epithelial-like cell lines [25]. All ZNF677 transfected 
cell lines demonstrated strongly downregulated expression 
of genes GH1, GH2, CSH1 and CSH2 which are involved in 
“JAK-STAT growth hormone signaling pathway” compared 
to control cells. These highly homologous genes are involved 
in normal postnatal growth regulation [26]. Interestingly, 
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elevated GH concentrations were found in serum samples of 
breast cancer patients and an association between autocrine 
GH1 expression and hyperproliferation of breast cancer cells 
was reported [27, 28]. However, the role of these growth 
regulators in NSCLCs is unclear and needs to be determined. 
In contrast, genes whose expression was seen to be 
upregulated in ZNF677 transfected cell lines were found to 
be mainly involved in “type I interferon signaling pathway” 
and in “response to virus”. While interferon stimulating gene 
IRF9 is a key factor forcing the anti-proliferative effect of 
IFN-α, ISG15 is involved in a Wnt/beta-catenin suppressing 
pathway and may inhibit liver cancer cell growth [29–32]. 
The function of other interferon stimulated genes like IFIT1, 
IFIT2 and IFIT3 is yet poorly understood.
Overall, we identified methylation as the major 
mechanism for frequent transcriptional inactivation of 
ZNF677 in NSCLCs. ZNF677 methylation occurs tumor-
specific in NSCLC patients and might be of potential 
prognostic impact for these patients. Moreover, we observed 
a strong tumor cell growth suppressing effect of ZNF677 
and we identified certain pathways affected by ZNF677 
which are involved in regulation of cell proliferation. 
All these results together indicate that ZNF677 plays an 
important role in the pathogenesis of NSCLCs.
MATERIALS AND METHODS
Tumor cell lines and tissue samples
Lung adenocarcinoma cell lines A549, NCI-H1993 
and NCI-H2073 were purchased from the American 
Type Culture Collection (ATCC) and were stored in 
liquid nitrogen until use. Lung adenocarcinoma cell lines 
Calu6, HCC827 and NCI-H1975 were kindly provided by 
Dr. Walter Berger (Institute of Cancer Research, Medical 
University of Vienna, Vienna, Austria). Normal human 
bronchial epithelial cell (NHBECs) pellets were purchased 
from Promocell. Tumor cells were cultured and treated 
with a combination of Aza-dC and TSA as reported [8]. 
Untreated cells were used as controls.
Genomic DNA of breast cancer (BT-20, MCF-7, 
MDA-MB-231, MDA-MB-453, MDA-MB-468), colon 
cancer (HCT-15, HT-29), ovarian cancer (SCOV3, A2780), 
pancreatic cancer (AsPC-1, BxPC-3) and head and neck 
cancer (Cal-27, FaDu) cell lines was obtained from members 
of the Medical University of Vienna, Vienna, Austria.
Frozen primary TU and corresponding NL specimens 
of a convenience sample of 147 stage I, II or III caucasian 
NSCLC patients who underwent surgical resection of their 
tumor in a curative intent during the years 2000–2004 were 
used. Overall, from 97 patients clinico-pathological data 
including gender, age, histology, tumor stage, lymph node 
stage, stage of disease, disease recurrence, disease-free 
survival (DFS) and overall survival (OS) were collected 
[7]. The median age was 62 years and the median follow-
up time was 54 months. None of these 97 patients received 
adjuvant chemotherapy. This study was approved by the 
local ethics committee of the MUV. From 35 of these 
patients also formalin-fixed, paraffin embedded (FFPE) TU 
and NL samples were available.
Publicly available datasets
Affymetrix HG-U133_ plus_2.0 gene expression 
microarray data were obtained from ArrayExpress 
database and the datasets E-GEOD-18842 and 
E-GEOD-19188 were used [13, 14, 33].
RNA-seq data, Affymetrix SNP array data and Agilent 
aCGH data were obtained from “The Cancer Genome Atlas” 
(TCGA) database (http://cancergenome.nih.gov), from 
cBioPortal for Cancer Genomics (http://www.cbioportal.
org) and from Cancer Browser (https://genome-cancer.ucsc.
edu/) [34]. The following datasets were used: lung cancer 
(LUAD and LUSC), colon and rectum adenocarcinoma 
(COADREAD), kidney clear cell carcinoma (KIRC), head 
and neck squamous cell carcinoma (HNSC), breast invasive 
carcinoma (BRCA) and uterine corpus endometrioid 
carcinoma (UCEC). Caleydo software and Cancer Browser 
(https://genome-cancer.ucsc.edu) were used for data 
visualization [17, 35]. A detailed overview about all these 
datasets is shown in Table 1.
Real-time reverse transcription-PCR (RT-PCR)
Total RNA was isolated from NHBECs and NSCLC 
cell lines using TRIzol reagent (Invitrogen) and reverse 
transcribed using OmniScript Reverse Transcriptase 
Kit (Qiagen). ZNF677 expression was determined 
by RT-PCR using Taqman Gene Expression Assays 
(Applied Biosystems) Hs00737026_m1 (ZNF677) 
and Hs03929097_g1 (GAPDH). Differences in gene 
expression were calculated by standard ∆∆Ct method [36].
Methylation-sensitive high resolution melting 
(MS-HRM) analyses
Genomic DNA was isolated from NHBECs, tumor 
cell lines and frozen tissue samples as reported and was 
stored at −80°C until use for methylation analyses [8]. 
Afterwards, genomic DNA was modified by treatment 
with sodium bisulfite using EpiTect Bisulfite kit (Qiagen) 
[37]. Primers (fwd, 5′-GTTTTTYGGGTTTAAGTTTG-3′ 
and rev, 5′-AATTTTAACCTACAAAACRACC-3′) 
were designed based on the genomic ZNF677 sequence 
obtained from ENSEMBL database (release 69) using 
Methyl Primer Express v1.0 software. EpiTect HRM 
PCR kit in a RotorGene®Q cycler (Qiagen) was used. 
Methylation standards were constructed by diluting 100% 
methylated and unmethylated control DNA (Qiagen) at 
100%, 75%, 50%, 25%, 10% and 0% ratios [37]. The 
standards were included in each HRM run performed. All 
experiments were performed in duplicate.
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Bisulfite genomic sequencing (BGS)
BGS was performed on sodium bisulfite treated 
genomic DNA as reported previously [7, 37]. Primers 
(fwd, 5´-TTTAAGGGAATTTAAAAGTGAAGAA-3´ and 
rev, 5´-TCCACACTAACCTAAAACAAAAAA-3´) were 
designed using Methyl Primer Express v1.0 software. 
PCR products were cloned using TOPO® TA Cloning® 
Kit for Sequencing (Invitrogen). Four clones per cell line 
(NHBECs, A549, Calu6 and NCI-H2073) were sequenced 
using M13 primers [7, 37].
Immunohistochemistry (IHC)
ZNF677 protein expression was determined 
in FFPE TU and NL samples of 35 NSCLC patients 
who were also included in our ZNF677 methylation 
analysis. A tissue microarray was constructed and used 
as reported previously [7]. The rabbit polyclonal anti-
ZNF677 antibody (1:10, HPA024796, Sigma Aldrich) 
was used. Results of IHC were scored as no staining 
(−), weak staining (1+), moderate staining (2+) or 
strong staining (3+). For comparison of IHC results 
Table 1: Summary of NSCLC gene expression microarray datasets obtained from ArrayExpress 
database and RNA-seq datasets obtained from TCGA / Cancer Browser databases used for ZNF677 
expression analyses
ID
ArrayExpress TCGAa
E-GEOD-18842b E-GEOD-19188c LUADd LUSCe
TU samples (N) 46 91 470 483
NL samples (N) 45 65 58 50
Matching TU/NL (%) 96 100 100 100
Sex N = 461 N = 408
Male (%) n/a 72 46 75
Female (%) n/a 28 54 25
Ethnicity N = 393 N = 317
Caucasian (%) n/a 89.5 92 92
Asian (%) n/a 0 2 3
Afro-American (%) n/a 0 6 5
Other (%) n/a 4 0 0
Unknown (%) n/a 6.5 0 0
Histology (%)
ADC 30 49 100 0
SCC 70 30 0 100
LCC 0 21 0 0
Disease stage (%)
I 83 60 54 50
II 9 28 24 30
III 6 9 17 18
IV 2 3 5 2
aClinical data based on Caleydo software using TCGA datasets version 15.01.2014,
bSanchez-Palencia et al., Int J Cancer, 2011;
cHou et al., PLos One, 2010;
dTCGA Research Network, Nature, 2014;
eTCGA Research Network, Nature, 2012. TU, primary tumor; NL, non-malignant lung tissue; ADC, adenocarcinoma; SCC, 
squamous cell carcinoma; LCC, large cell carcinoma.
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with methylation results, patients whose TU showed no 
or weak staining were grouped as “negative by IHC” 
while patients whose TU showed moderate or strong 
staining were grouped as “positive by IHC” as reported 
previously [7].
Vectors and transfection
pCMV6-ENTRY (empty control, PS100001, Origene) 
and pCMV6-ZNF677 (RC207997, Origene) were used 
for transfection experiments. A pCMV6-GFP vector was 
constructed by subcloning the GFP coding sequence using fwd 
(5′-GAGGCGATCGCCATGGTGAGCAAGGGCG-3′) and 
rev (5′-GCGACGCGTCTTGTACAGCTCGTCCATG-3′) 
primers. Cells were transfected by use of Lipofectamine® 
LTX reagent (Invitrogen) as recommended by the 
manufacturer. Stably transfected cells were selected by 
G418 treatment (Invitrogen) and transfection efficacy was 
analysed by RT-PCR and Western blotting.
Western blotting
Protein samples were denatured, separated by 
SDS/PAGE and transferred onto PVDF membrane 
(Biorad). Membranes were blocked followed by 
incubation with primary antibodies anti-ZNF677 (1:100, 
Abcam), anti-IRF9 (1:50, Santa Cruz Biotechnology), 
anti-ISG15 (1:1000, Cell Signaling), anti-CSH1 (1:375, 
Thermo Scientific), anti-ACTB (1:200, Abcam) and 
anti-GAPDH (0.05mg/ml, Sigma Aldrich). Appropriate 
secondary HRP antibodies were used and membranes 
were visualized using ECL Western blotting substrate 
(Thermo Scientific).
Cell viability and cell proliferation
CellTiter-Blue® Cell Viability Assay (Promega) 
was performed as recommended. Cells were seeded in 
triplicate in 96-well plates and incubated with CellTiter™ 
Blue reagent prior to fluorescence measurement.
xCELLigence Real-Time Cellular Analysis (RTCA) 
system (Roche) was used to measure cell proliferation 
in real time. Cells were seeded in triplicates in 16-well 
E-plates, cell proliferation was continuously monitored for 
1 week and the cell index was recorded every 5 minutes by 
the RTCA analyzer.
Caspase assay
Fluorometric caspase assay was performed 
as described [38, 39]. Cell lysates were 
incubated with caspase 3 substrate (Enzo) in 
HEPES buffer. Caspase substrate cleavage was 
measured at an excitation wavelength of 405 nm 
and an emission wavelength of 535 nm. Reaction mixture 
without protein was used for background correction. Cells 
treated with Doxorubicine were used as positive control.
Scratch assay
A cell monolayer was scratched with a sterile pipette 
tip and cells were incubated under standard conditions. 
The scratch was observed under light microscopy and was 
photographed at several time points.
RNA-sequencing (RNA-seq)
Total RNA was prepared from transfected and 
control cells of NSCLC cell lines using RNeasy 
kit (Qiagen) and was subjected to RNA-seq according the 
mRNA sequencing protocol provided by Illumina (TruSeq 
RNA Sample Preparation Kit) as reported previously 
[40]. In brief, poly(A)-containing mRNA molecules were 
purified using poly(T)-oligo-attached magnetic beads, 
fragmented and applied to first-strand complementary 
DNA (cDNA) synthesis using reverse transcriptase and 
random primers. Second-strand cDNA synthesis was 
performed using DNA polymerase I and RNase H. cDNAs 
were then end-repaired, A-tailed, ligated to adaptors and 
amplified to create the final cDNA library. Afterwards, 
adaptor-ligated cDNA was sequenced on a HiSeq2000 
sequencer according to the manufacturer′s instructions.
Statistical analysis
Raw Affymetrix microarray data were processed 
and normalised using MAS5 algorithm of Flexarray 1.6 
software [41]. Differences in gene expression between 
tissue types were calculated using ANOVA and resulting 
p-values were adjusted for all probe sets represented on 
Affymetrix HG-U133_plus_2.0 microarrays (54.675) 
using Bonferroni method. An adjusted p-value < 0.05 was 
considered as statistically significant.
Wilcoxon signed rank tests were used to calculate 
ZNF677 methylation differences between TU and NL 
samples obtained by MS-HRM analyses. Receiver operating 
characteristic (ROC) curve analysis was performed 
using GraphPad Prism 6 software. A p-value < 0.05 was 
considered as statistically significant. Spearman’s Rho test 
was calculated for correlation of methylation and gene 
expression data from TCGA datasets using R software.
MS-HRM data were compared with clinico-
pathological characteristics (gender, age, histology, tumor 
stage, lymph node stage, stage of disease, disease recurrence, 
DFS and OS) of NSCLC patients. Chi2 tests/Fisher’s exact 
tests were used to calculate differences between groups and 
t-tests were used to calculate differences between means. 
Survival analyses of patients were performed using log rank 
and generalized Wilcoxon testing. A p-value < 0.05 was 
considered as statistically significant. These analyses were 
performed using the statistics software PASW (version 18).
Galaxy platform and TopHat2 were used to align raw 
RNA-seq data (fastq files) of ZNF677 transfected NSCLC 
cells and of control cells to hg19 [42–45]. Aligned .bam 
files were imported to SeqMonk v0.27.0 software and 
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processed using RNA-seq quantitation pipeline (http://www 
.bioinformatics.babraham.ac.uk/projects/seqmonk/). An 
adjusted p < 0.05 was defined as cut-off for differentially 
expressed genes.
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